One measure was the putative KRAS-dependency gene expression signature derived from a panel of human KRAS mutant cancer cell lines that differed in the survival and differentiation on continued KRAS expression13; and the second was an expression signature derived from our in vivo single-cell RNA sequencing data (36 genes with significantly greater expression in the epithelial cells of KRAS intact compared to KRAS KO tumors, Supplementary Table 1). This evidence concerns the gene KRAS and cancer.